Swiss Rockets Acquires California Based Complete Genomics

The acquisition enables Swiss Rockets AG to expand its capabilities in precision medicine and wellness, integrating advanced DNA sequencing to accelerate the development of targeted cancer therapies and next-generation vaccines.

Founded in 2018 in Basel, Swiss Rockets AG is transforming healthcare through innovative cancer therapies.

Read Also - Zurich’s Fainite AG Secures €165K From Venture Kick To Advance Physics-Based Simulations

The company combines deep expertise and disruptive methods to develop breakthrough medicines delivering impactful results for patients, inventors and investors and driving a paradigm shift in precision medicine and global healthcare innovation.

Founded by Dr. Rade Drmanac, Complete Genomics offers end-to-end DNA sequencing platforms, reagents, and software, supporting over 10,900 scientific publications with its high-throughput technology.

Under Founder, CEO, and Chairperson Dr. Vladimir Cmiljanovic, Swiss Rockets supports biotech and precision healthcare companies through an incubator model focused on oncology, radioligand therapies, and live-attenuated virus vaccines.

About Complete Genomics

Headquartered in San Jose, California, Complete Genomics is a pioneering life sciences company founded in 2005. The company drives genomics forward by providing end-to-end high-throughput sequencing solutions that advance research improve healthcare outcomes and enable scientific breakthroughs solidifying its leadership in the field of genomic technology.